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Introduction
The ethical challenges currently presented by testing for 
single nucleotide polymorphisms (SNPs) and copy number 
variants  (CNVs)  in  medical  practice  are  sufficiently 
different to require separate discussions. The nature of any 
uncertain significance is somewhat different for SNPs and 
CNVs. In addition, SNPs can be divided into those known 
to be associated with single gene disorders and those that 
can provide risk modification for common diseases.
SNP testing
The technologies used to analyze SNPs are not intended 
to  discover  new  point  mutations,  but  rather  to  detect 
ancient  genotypes  carried  by  thousands  of  people  (for 
example, apolipoprotein E4, Online Inheritance in Man 
(OMIM)  ID  104310)  and  sickle  cell  mutation 
(OMIM-603903);  they  also  can  detect  recurrent  new 
mutations (for example, achondroplasia, OMIM-100800). 
Numerous  laboratories  are  offering  SNP  testing  for 
ances  try or disease risks, separately or in combination. 
These  include  23andMe  [1],  deCODE  [2],  Pathway 
Genomics  [3],  and  Navigenics  [4].  The  Department  of 
Molecular  and  Human  Genetics  at  Baylor  College  of 
Medicine [5] and some of these providers offer testing 
focused on less common mutations that establish a diag-
nosis of a single gene disorder. At least two labora  tories 
are offering expanded carrier testing for recessive disease 
risks  to  prospective  parents;  these  are  23andMe  and 
Counsyl [6]. Many laboratories are offering pharmaco-
genetic testing, which determines a wide range of geno-
types.  Laboratories  vary  widely  with  respect  to  the 
combi  nations of genotypes they focus on, out of ancestry, 
risk probability, single gene diagnosis, pharmacogenetics, 
and  carrier  testing.  It  is  very  difficult  to  compare  the 
offerings  of  different  laboratories  using  their  websites, 
because  they  generally  do  not  provide  complete  infor-
mation on exactly which SNPs are scored.
Clinical utility of SNP genotyping
There is a gradation of clinical utility of SNP genotyping, 
starting with SNPs actually conferring a diagnosis of a 
single  gene  disorder.  Examples  of  such  disorders  that 
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(OMIM-188055),  hemochromatosis  (OMIM-235200), 
and  α1-antitrypsin  deficiency  (OMIM-107400).  Other 
dis  orders are less common, and therefore technically not 
frequent enough to qualify as common polymorphisms, 
but are still not rare; these include recurrent or widely 
distributed mutations causing hereditary non-polyposis 
colon cancer (HNPCC, Lynch syndrome (OMIM-120435), 
Li-Fraumeni  syndrome  (OMIM-151623),  breast  and 
ovarian cancer caused by BRCA1 or BRCA2 mutations 
(OMIM-113705 and OMIM-600185), and heterozygous 
familial hypercholesterolemia (OMIM-143890)). Also of 
high utility is testing for recessive mutations that confer 
carrier status and for which there is the risk of having an 
affected child if a reproductive partner is also a carrier for 
the same locus; examples would be disorders such as Tay 
Sachs  disease  (OMIM-272800),  cystic  fibrosis  (CF, 
OMIM-219700), or sickle cell anemia.
Of intermediate utility would be SNP genotypes that do 
not represent a single gene disorder but that confer risk 
modification of substantial magnitude; examples would 
be the APOE4 genotype and risk of Alzheimer’s disease 
(OMIM-104310)  and  genotypes  related  to  risk  of  age-
related  macular  degeneration  (OMIM-603075).  Then 
there are very common SNP genotypes of less utility that 
confer very modest risk modification for common dis-
orders, such as type 2 diabetes mellitus [7]. SNPs used to 
determine ancestry have little medical utility. Finally, the 
vast majority of SNPs on many widely used commercial 
arrays have absolutely no known medical utility. Each of 
these categories raises distinct ethical issues.
General ethical issues in SNP testing
One ethical and medical question is whether combining 
SNPs of the five types mentioned above, in the same test, 
is  appropriate.  Ancestry  testing  is  largely  for  curiosity 
and perhaps recreational interest. Although ancestry can 
influence medical decisions and testing for single gene 
disorders and carrier testing, there is no evidence that 
ancestry testing by SNPs has greater medical value than 
the  information  available  from  history  and  physical 
exami  nation.  Testing  for  risk  modification  has  some 
medical value, although most of the SNPs used in this 
way could be considered to be of limited clinical utility. 
Risk modifications of less than two-fold would rarely be 
medically actionable, although a small increased risk of 
type 2 diabetes or hypertension might motivate a patient 
to pursue an exercise program and control weight more 
than they might otherwise. The testing offered by some 
providers combines ancestry and disease risk modifica-
tion, although the two can often be ordered separately. 
The coverage for mutations that establish a single gene 
disorder varies widely among providers. Although it is 
technically  feasible  to  combine  any  of  these  forms  of 
testing with reproductive carrier testing, it is  probably 
best to keep this form of testing separate, as most but not 
all providers are doing at present.
There is a potential conflict when laboratories fail or 
refuse  to  provide  detailed  information  about  precise 
geno  types  being  tested.  They  may  consider  this  infor-
mation proprietary. The US National Institutes of Health 
has just announced the intent to create a Genetic Testing 
Registry, an ‘online resource that will provide a central-
ized  location  for  test  developers  and  manufacturers  to 
voluntarily submit test information such as indications 
for use, validity data, and evidence of the test’s usefulness’ 
[8]. Given that this initiative is voluntary, it may or may 
not improve information sharing.
One of the most debated ethical questions at present is 
the  offering  of  direct-to-consumer  testing.  The  availa-
bility of such services through 2003 was reported [9]. The 
American College of Medical Genetics issued a statement 
in  2004  opposing  direct-to-consumer  testing  [10].  The 
European  Society  of  Human  Genetics  has  published  a 
discussion from a November 2009 meeting [11]. Other 
recent discussions are available [12,13], and one publica-
tion  describes  differences  in  reports  when  the  same 
samples  were  submitted  to  23andMe  and  Navigenics 
[14]. Some forms of direct-to-consumer medical testing 
are widely accepted, as exemplified by home pregnancy 
testing.  However,  when  broad  testing  panels  include 
genotypes  with  substantial  risks,  such  as  APOE4  for 
Alzheimer’s,  mutations  in  mismatch  repair  genes  for 
HNPCC,  and  BRCA1/BRCA2  mutations  for  breast 
cancer,  the  involvement  of  counselors  or  physicians  is 
essential, and simply having counselors available at the 
discretion  of  the  person  being  tested  is  not  sufficient. 
Presumably requiring that only physicians or counselors 
could communicate results would be one alternative.
Testing for genotypes underlying a single gene disorder
For  genotypes  conferring  a  diagnosis  of  a  single  gene 
disorder, such as factor V Leiden or hemochromatosis, 
the risk-benefit ratios are among the most favorable, but 
even here there are concerns that such testing is not cost 
effective,  is  not  evidence  based  and  may  lead  to 
stigmatization or undue anxiety [15,16]. Assuming low-
cost and high-throughput genotyping and good physician 
and patient education, this form of testing carries rela-
tively few ethical concerns in my view. If physician and 
patient education are lacking, inappropriate outcomes or 
management may result.
Evidence-based practice should dictate any change in 
management based on genotype. With proper physician 
and patient comprehension, there are potential clinical 
benefits and relatively little downside to knowing that an 
individual is at increased risk of thrombosis related to 
factor  V  Leiden,  emphysema  related  to  α1-antitrypsin 
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physicians  have  routinely  incorporated  factors  such  as 
obesity,  blood  pressure,  and  low-density  lipoprotein 
cholesterol into management decisions, the physician of 
the  21st  century  should  incorporate  genotype  into 
manage  ment decisions. The potential clinical benefits for 
the  less  common  but  quite  serious  genotypes  for 
HNPCC,  heterozygous  familial  hypercholesterolemia, 
and BRCA1/BRCA2 are perhaps even more compelling. 
One  can  make  a  strong  argument  that  premature 
mortality  and  morbidity  can  be  avoided  by  proper 
monitoring and intervention for these disorders. From an 
ethical perspective, there may be a growing responsibility 
for physicians to offer these forms of testing.
For  carrier  testing  for  recessive  mutations,  there  is 
well-established precedent and published evidence [17] 
that  carrier  testing  for  disorders  such  as  Tay  Sachs 
disease,  thalassemia,  CF,  and  sickle  cell  anemia  can 
reduce  the  frequency  of  these  disorders  among  births. 
Medical practice guidelines in many countries strongly 
suggest that couples should be offered carrier testing for 
specific diseases. The primary ethical issues for carrier 
testing relate to religious and other guiding principles as 
to  which  reproductive  behaviors  are  acceptable  and 
appro  priate.  The  primary  approach  used  to  avoid  the 
birth of affected children has been prenatal diagnosis and 
termination  of  affected  pregnancies,  although  other 
approaches  such  as  genotyping  to  identify  and  avoid 
‘risky matches’ have been used. Abortion based on fetal 
genotype  is  possible,  but  is  ethically  unacceptable  to 
many individuals and is illegal in many parts of the world. 
For couples at 1 in 4 risk (such as when both carry a CF 
mutation) or 1 in 2 risk (such as an HNPCC mutation) of 
having  an  affected  offspring,  preimplantation  genetic 
diagnosis may be a very attractive option that would have 
wider  but  not  complete  acceptance  ethically,  although 
high costs and risks of twin and higher multiple pregnan-
cies are still a concern with this approach.
If  one  accepts  that  offering  carrier  testing  for  some 
disorders  (for  example,  Tay  Sachs  disease)  is  good 
medical  practice,  then  testing  for  other  disorders  of 
similar severity (such as Hurler mucopolysaccharidosis) 
would  seem  ethically  desirable.  Testing  for  all  known 
recessive  mutations  for  individual  loci  is  theoretically 
possible,  and  sensitivity  for  detection  of  carriers  will 
improve  over  time.  Counsyl  claims  that  its  testing  is 
‘shown to be more than 99.9% accurate for more than 100 
serious genetic diseases’ on its website as of April 2010 
[6]. Although this may be true for detection of a specific 
genotype,  it  is  not  true  if  (as  readers  might  assume) 
accuracy is defined as ability to distinguish carriers and 
non-carriers reliably. The ability to detect carriers varies 
by locus, but no ethical principle argues against testing if 
only a proportion of carrier couples are detected so long 
as  proper  education  and  counseling  explain  this 
limita  tion.
There  are  major  ethical  controversies  in  deciding 
whether carrier testing for less severe disorders such as 
recessive deafness is appropriate or not. Individuals and 
societies  are  probably  rather  divided  on  whether  it  is 
ethical to terminate a pregnancy because of the presence 
of a connexin 26 genotype (OMIM-121011) causing deaf-
ness. At present or in the future in the US medicolegal 
context,  the  availability  of  carrier  testing  and  prenatal 
diagnosis for some forms of deafness could lead to an 
obligation  to  inform  couples  of  this  [18].  Perhaps  it  is 
reassuring  that,  to  my  knowledge,  couples  and  those 
offering testing have not found the phenotype of color-
blindness (for example) suitable for carrier or prenatal 
testing. In this case, a large fraction of individuals and 
societies  might  find  such  testing  to  be  ethically 
unaccep  table.
CNV testing
Although point mutations and CNVs can give rise to the 
same  phenotype  (for  example,  neurofibromatosis, 
OMIM-162200), generally the ethical issues surrounding 
CNVs  are  very  different  from  those  related  to  SNPs. 
Much of the knowledge of the medical relevance of CNVs 
to  disease  is  very  recent  and  sometimes  alarmingly 
incomplete. Although deletion CNVs causing DiGeorge 
syndrome,  Williams  syndrome,  and  many  other  syn-
dromes have been known for decades, the importance of 
other  CNVs,  such  as  deletions  and  duplications  of 
chromo  some 16p11.2 and duplications of the Williams 
syndrome  region  was  discovered  just  in  the  past  few 
years [19]. Testing in medical practice began as a method 
to identify an etiology, often but not always de novo, in 
children with mental retardation (intellectual disability), 
birth defects, and other developmental disabilities. To the 
extent that such CNVs are de novo and have 100% pene-
trance  for  a  severe  phenotype,  analysis  provides  the 
medical benefits of knowing the etiology of that pheno-
type, and the data allow much improved genetic counsel-
ing  of  families,  although  there  is  rarely  any  genotype-
specific  treatment  as  yet.  The  ethical  difficulties  are 
limited  in  such  cases.  Much  greater  ethical  difficulties 
arise when penetrance is incomplete (not everyone with 
the genotype has an abnormal phenotype); when there is 
variable  expression  (those  with  the  genotype  and  an 
abnormal phenotype vary widely as to the nature and/or 
severity  of  their  phenotype);  or  when  there  is  great 
uncertainty as to whether there is any phenotypic risk 
whatsoever for a given CNV.
Issues raised by CNVs with incomplete penetrance
A likely example of incomplete penetrance is deletion of 
chromosome  15q13.3.  Many  children  with  this  CNV 
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criteria  for  a  diagnosis  of  autism.  This  deletion  is  also 
associated with schizophrenia, bipolar disorder, epilepsy, 
and perhaps antisocial behaviors [20,21]. However, it is 
not rare [20] to find a parent with the deletion who is 
con  sidered  by  themselves,  their  family,  and  their 
physicians to be normal. This would seem to represent 
lack  of  penetrance.  Let  us  suppose  for  the  sake  of 
discussion that 70% of individuals with this duplication 
have clear developmental disabilities, that 15% are near 
normal but have mild disabilities that generally would 
be seen as within the range of what is ‘normal’ in the 
population, and that 15% are completely normal with no 
phenotypic  effect  from  the  genotype.  Imagine  that  a 
parent had some learning difficulties in school, or that 
the IQ of such apparently unaffected individuals with 
the deletion was statistically significantly lower than for 
their non-deletion siblings, but the majority of the IQs 
are  still  within  the  normal  range.  Imagine  that  this 
parent  and  their  partner  go  to  the  internet  and  read 
about the circumstances posed here. There certainly are 
societal challenges. Is it ethical or unethical to explain 
all this on a public website? Will parents with borderline 
phenotypes  be  harmed,  traumatized,  or  stigmatized? 
Will  they  see  themselves  differently  and  will  their 
partner  see  them  differently?  Could  family  members 
with  the  deletion  geno  type  but  a  completely  normal 
phenotype be stigmatized?
Issues raised by CNVs of uncertain significance
Another situation arises when CNVs of uncertain signifi-
cance occur with typical frequencies of 1 in 50 to 1 in 500 
in the general population. These CNVs are usually first 
observed  in  patients  with  developmental  disabilities 
because this is the population being tested. These initial 
observations often result in publications of one or a few 
patients suggesting that the CNV might cause the dis-
ability phenotype in the patients. However, these CNVs 
could be completely benign, with the association with a 
phenotype being entirely coincidental. Alternatively, even 
if  a  normal  parent  has  the  CNV,  there  could  be 
incomplete penetrance, and the CNV may be the cause of 
the phenotype in the child. What should the laboratory 
report to the physician and what should the physician tell 
the family? Should the information be withheld by the 
laboratory or the physician because the genotype is of 
uncertain significance? It may be preferable to explain the 
findings and all the uncertainties and to keep the family 
well informed as new information accumulates over the 
next year or two or more. However, this may be very time 
consuming and may result in undue anxiety or distress 
for the family.
The  detection  of  a  CNV  with  known  pathological 
effects but known incomplete penetrance or of a CNV of 
very uncertain significance is particularly difficult when 
the  test  is  performed  for  prenatal  diagnosis.  Array 
methodology  has  already  largely  replaced  karyotype 
methods for diagnosis of pediatric disabilities [22], and a 
similar transition is expected for prenatal testing, but a 
CNV  of  uncertain  phenotypic  significance  presents 
greater  ethical  difficulties  in  the  prenatal  setting.  Our 
experience  has  been  that  findings  of  troublesome 
uncertain  significance  occur  in  about  1%  of  routine 
prenatal samples [23]. Families seem not to be excessively 
distressed  by  findings  of  uncertain  significance  and 
generally are quite comfortable if the finding is present in 
a normal parent, although this does not guarantee that 
the CNV is benign. De novo CNVs appropriately raise 
greater  concern,  but  these  still  may  be  benign.  In  the 
prenatal setting, these 1% of cases are often discussed by 
a group of experts before information is shared with the 
family.  Decisions  of  families  are  heavily  influenced  by 
their  previous  willingness  to  accept  any  increased  risk 
and  by  their  attitudes  regarding  abortion.  I  have  not 
observed pregnancy terminations in instances in which 
my  colleagues  and  I  felt  that  the  statistical  risk  of  a 
disability phenotype was real but relatively low. I believe 
that the improved prenatal diagnosis of many disorders 
provided  by  array  tests  compared  with  the  traditional 
karyotype outweighs the uncertainties for families who 
would  terminate  pregnancies  with  findings  firmly 
associated with severe disabilities.
One relatively new ethical difficulty arises when SNP 
arrays are used to evaluate children with disabilities; and 
it is likely that combined SNP and copy number arrays 
will be more widely used going forward. These arrays can 
easily identify blocks of absence of heterozygosity that 
occur  on  the  basis  of  uniparental  disomy  or  consan-
guinity.  This  can  be  helpful  in  diagnosing  uniparental 
disomy  causing  disorders  such  as  Prader-Willi  and 
Angelman syndromes and in identifying candidate gene 
regions for disease in children born of first cousin and 
similar matings. However, the occurrence of incest, as in 
the mating of a parent and child or between siblings, is 
immediately obvious because about one-quarter of the 
genome  shows  absence  of  heterozygosity  because  of 
identity  by  descent  (ALB,  unpublished  observations). 
There  is  limited  information  as  to  the  frequency  with 
which  developmental  disabilities  are  caused  by  inces-
tuous matings, but the frequency of intellectual disability 
is high in such offspring [24]. Now, with SNP arrays, such 
cases of incest will be readily identified with a test that 
will  be  widely  applied  for  evaluation  of  children  with 
disabilities;  no  parental  sample  is  required  for  a  near 
certain  recognition  that  a  child  was  born  from  an 
incestuous mating. This may often involve sexual abuse 
of young children in the home. If one parent is below a 
certain  age,  child  abuse  laws  may  require  reporting  to 
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clear whether the physician would be legally obliged to 
report the finding to authorities.
Governmental regulation
There  are  two  areas  in  which  the  role  of  government 
comes up for genetic testing: gene patents, and regulation 
of laboratories and testing. Is it ethical, legal, or desirable 
to  allow  gene  patents  that  can  limit  the  availability  of 
testing or increase the cost? Policies related to diagnostic 
gene patents vary widely around the world. Gene patents 
have  been  issued  in  the  US,  although  a  recent  court 
decision struck down some BRCA1 and BRCA2 patents. 
The final word on gene patents in the US is likely to await 
a Supreme Court decision. The European Patent Office 
revoked  diagnostic  patents  for  BRCA1  and  BRCA2  in 
2004.
On  the  matter  of  regulating  genetic  testing,  the  US 
Food  and  Drug  Administration  (FDA)  has  asserted  its 
authority and intent to regulate such testing, but most 
SNP and CNV testing is not FDA approved at present. 
Again, policies vary widely across the world, with most 
regulatory efforts in their infancy. The FDA has begun 
specifying  that  certain  pharmacogenetic  testing  is 
desirable  or  perhaps  mandatory  prior  to  prescribing 
some medications, and this approach is likely to expand 
and be used in many countries.
One  final  question  is  whether  regulations  should 
require that the requesting physician or the patient must 
have access to all the CNV or SNP genotype data. For 
CNVs, it is probably common at present that two differ-
ent genetic laboratories might detect the same CNV, and 
one laboratory would report it back to the physician as 
being  of  uncertain  significance  whereas  the  second 
labora  tory  might  not  report  the  finding  at  all. 
Alternatively, two laboratories might report a CNV but 
provide somewhat different interpretations as to whether 
the CNV is pathogenic or not. For SNP genotypes, differ-
ent  interpretations  have  been  reported  from  different 
laboratories,  as  noted  above  [14].  In  addition,  it  is 
possible  that  the  interpretation  provided  for  a  specific 
SNP genotype in 2010 might be very different from that 
given in 2015. Although a case can be made for having 
genotypic data become part of the (hopefully electronic) 
medical record, this is not common at present. This also 
raises the question of whether the physician or patient 
should  have  the  ability  to  obtain  a  second  opinion 
regarding the interpretation of the data. One attractive 
option  would  be  to  have  a  group  of  professionals  that 
might  be  called  ‘genomicists’  who  would  provide  a 
second  interpretation  analogous  to  that  which  a 
radiologist  or  pathologist  might  provide  today  for  a 
magnetic  resonance  image  or  a  histology  slide, 
respectively.
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